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Fever vs. Drug: Battling with the Brugada syndrome substrate 
 
Brugada syndrome (BrS) and associated life threatening ventricular arrhythmias (VA) are a 
leading cause of sudden cardiac death (SCD) in the young, especially in South East Asia (1). 
The presence of the Type 1 Brugada ECG pattern in the ECG leads overlying the right 
ventricular outflow tract (RVOT), spontaneously or provoked by sodium channel blockers or 
by fever, is essential for the diagnosis (2). The specificity of the type 1 pattern induced by 
pyrexia or sodium channel provocation is uncertain. A 2% prevalence of the type 1 pattern 
was noted in consecutive patients presenting to an Israeli ED with fever (3), whilst 4% of 
healthy Turkish controls undergoing ajmaline provocation developed the type 1 pattern (4). 
This has led to refinements in the diagnostic criteria for BrS, including a diagnostic scoring 
system, the Shanghai Score (1). Fever or drug-induced Type 1 pattern alone are no longer 
diagnostic without evidence of further clinical or familial features although fever was given 
a greater weighting in the scoring system.  
 
There are electrocardiographic differences between fever-induced and drug-induced type 1 
patterns. A drug-induced pattern was reproduced in only 81% of cases presenting with an 
initial fever-induced pattern. The drug-induced pattern was associated with significant PR 
and QRS prolongation, whilst the PR interval was shortened by fever (5). The same study 
suggested a higher risk associated with a fever-induced pattern although Adler et al. had 
found a good prognosis (3). It seems that provoked type 1 patterns are a relatively common 
finding. 
 
Understanding the pathophysiology of BrS is therefore critical to understanding these 
differences. Counter to the perception of BrS as a disease devoid of any structural features, 
there now exists significant evidence in favor of subtle abnormalities within the RVOT. 
Nademanee studied a group of BrS patients with recurrent VF, undertaking electromagnetic 
mapping of the right ventricular (RV) epicardium and endocardium demonstrating 
fractionated and late low voltage potentials within the RVOT epicardium. Radiofrequency 
catheter ablation (RFCA) within this region resulted in: elimination of the type 1 Brugada 
ECG pattern; non-inducibility of VF; and low recurrence rates (6). In BrS patients undergoing 
open thoracotomy and RVOT RFCA, these epicardial fractionated late potentials correlated 
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with epicardial and intramyocardial fibrosis on biopsy. Ablation at these sites was effective 
in eliminating the type 1 pattern and reducing event rates. The same arrangement of subtle 
epicardial RVOT fibrosis, coupled with altered expression of the gap junction protein 
Connexin-43, was detected in sudden cardiac death cases in whom surviving first degree 
relatives were found to have BrS (7).  
 
Brugada et al (8) analyzed the effect of flecainide on the epicardial substrate in a group of 
BrS patients with ICDs who were symptomatic with syncope or dizziness and were inducible 
at EP studies, and then underwent RFCA. Flecainide was shown to increase the area of low 
voltage fractionated signals within the RVOT and RV free wall. RFCA within these regions 
was effective in eliminating the BrS phenotype and inducibility.  
 
Enter the fascinating study by Chung et al published in this issue of the journal (9), who 
sought to explore the substrate of BrS further. Warm water was instilled into the epicardial 
space to induce local hyperthermia and mimic the effect of fever. Flecainide’s effects on the 
substrate and enhancement of epicardial premature ventricular complex (PVC) triggers 
were also examined with the hypothesis that this would allow a more efficacious strategy 
for RFCA encompassing PVC trigger ablation and substrate modification. This incorporated 
the original observations of Haissaguerre et al (10) who described the successful ablation of 
PVCs originating from the RVOT or right Purkinje conducting system, responsible for 
triggering VAs in specific patients with BrS.  
 
Fifteen BrS patients with a history of an aborted cardiac arrest (n=10) or VA with syncope 
(n=5) were recruited: eight patients had a spontaneous Type 1 pattern at baseline, with the 
remaining demonstrating a type 1 pattern with flecainide. All patients underwent flecainide 
administration to assess the effect on PVC burden. Two patients demonstrated an increase 
in PVC density whilst three patients had documented PVCs at baseline. PVCs originated from 
the RVOT (n=3) and left ventricular papillary muscle (n=2), the latter being a novel 
association in BrS.  Targeted RFCA resulted in successful elimination of these triggers. 
Substrate mapping identified abnormal epicardial electrograms and scar in the anterior RV 
free wall and RVOT in 11 patients who then went on to have successful epicardial substrate 
modification with immediate elimination of the BrS phenotype in five patients and then a 
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further two patients during follow up. All cases were rendered non-inducible with 
elimination of VA recurrences except in one subject. Chung et al have added further to the 
weight of evidence in favor of ablation as a valid therapeutic modality in high risk BrS 
patients (9).  
 
Warm water instillation was undertaken in six patients and resulted in a significant increase 
in the area of functional scar over the epicardial surface. Whilst there was little observed 
differences in abnormal electrograms, in contrast with Brugada et al’s findings of significant 
effects on electrogram morphology caused by flecainide (8), there were significant 
alterations of epicardial conduction velocities. These were reduced in areas in which 
functional scar was identified, whereas an increase in activation velocity was seen in 
epicardial areas devoid of scar, as well as the endocardium. Furthermore all these 
individuals were rendered inducible during warm water instillation when only one was 
inducible at baseline. This observed enhancement of heterogeneity in conduction within the 
RV and RVOT therefore suggests a primary mechanism for VF of epicardial reentry in 
patients with BrS with fever and may have implications for arrhythmogenesis in BrS in 
general. The specific effect of fever was also comparable to that described by Mizusawa et 
al (5) where the fever-induced type 1 pattern was accompanied by shortening of the PR 
interval in contrast with the more widespread impact of sodium channel blockers on 
conduction.  
 
Several clinical questions remain. Does fever-induced type 1 pattern indicate a higher long 
term risk than a drug-induced pattern? What is the place of trigger ablation in ablation 
strategies? given that more recent studies have included less severely affected patients, are 
we convinced about the role of RVOT RFCA in patients without VT storm and/or recurrent 
VAs? A first logical step is a robust and systematic randomized control trial of patients with 
sufficiently high event rates to permit a successful study over a reasonable length of time. 
The BRAVE Study (11) aims to investigate the efficacy and prognostic value of RVOT RFCA in 
symptomatic BrS patients compared to current therapy of ICD alone. This will provide 
valuable insight into the potential role for RFCA in long term risk reduction and whether in 
the future it may offer value for primary prevention in the asymptomatic patient.  
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